A risk-based approach is recommended for analytical method comparability for HPLC assay and impurities methods.
Theresa Natishan
Advertisement
Theresa Natishan is a director at Merck
Articles by Theresa Natishan
Advertisement
Latest Updated Articles
Analytical Method Comparability in Registration and Post-Approval Stages: A Risk-Based ApproachPublished: October 2nd 2014 | Updated:
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
Everything to Know About Pharmaceutical Tariffs in 2025
2
Building Resilience in Pharma: Our Top 10 Questions from CPHI Frankfurt
3
New Dosage Forms and Delivery Systems Driving 505(b)(2) Success
4
PharmTech Weekly News Roundup – Week of November 3, 2025
5
